Login to Your Account

Hydra Lands Potential $195M Deal With Pfizer On Pain Drugs

By Jim Shrine

Friday, July 27, 2007
Hydra Biosciences Inc. licensed rights to its TRPV3 antagonist program to Pfizer Inc. in a deal valued at up to $195 million. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription